NASDAQ$ANAB
Anaptysbio Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Anaptysbio's financial performance and business updates for Q3 2024 were reported.
AnaptysBio reported a net loss of $32.9 million for the third quarter of 2024, with collaboration revenue of $30.0 million. The company's cash and investments totaled $458.0 million, reiterating cash runway through year-end 2026. Clinical trial milestones for ANB032 and rosnilimab are anticipated in December 2024 and February 2025, respectively.
- Top-line Phase 2b data for ANB032 in atopic dermatitis is anticipated in December 2024.
- Top-line Phase 2b data for rosnilimab in rheumatoid arthritis is anticipated in February 2025.
- Phase 1 trial initiated in healthy volunteers for ANB033.
- Cash runway reiterated through year-end 2026, with cash and investments totaling $458.0 million as of September 30, 2024.
Headline financials
Revenue & EPS history
Anaptysbio · Revenue · Quarterly
$30M
Forward guidance
AnaptysBio anticipates several clinical trial milestones and value drivers, including top-line data for ANB032 and rosnilimab, and the initiation of a Phase 1 trial for ANB033.
Tailwinds
- Top-line Phase 2b data for ANB032 in AD anticipated in December 2024
- Top-line Phase 2b data for rosnilimab in RA anticipated in February 2025
- Phase 1 trial initiated for ANB033 in healthy volunteers in October 2024
- Plan to initiate enrollment for Phase 1 trial for ANB101 in healthy volunteers in Q1 2025
- GSK anticipates top-line data in H1 2025 from COSTAR Lung Phase 3 trial
Headwinds
- The timing of the release of data from the Company’s clinical trials is uncertain.
- The Company’s ability to find a licensing partner for imsidolimab or etokimab and the timing of any such transaction is uncertain.
- The company’s projected cash runway is subject to change.
- The potential to receive any additional royalties from the GSK collaboration is not guaranteed.
- The company’s ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates is subject to risk.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
-1.7%
Avg return
Earnings day
-1.5%
Avg return
5 days after
-2.2%
Avg return
30 days after
51%
20 / 39 earnings
Positive
+15.8%
Q4 2019
Best reaction
-71.3%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.7% | -7.0% | -20.1% | |
| Q4 2025 | +14.5% | +13.0% | +9.2% | |
| Q3 2025 | +3.5% | -2.2% | +27.7% | |
| Q1 2025 | +0.9% | +2.6% | +18.2% | |
| Q4 2024 | +4.8% | +2.1% | +15.5% | |
| Q3 2024 | +11.4% | +6.9% | +18.7% | |
| Q2 2024 | -2.1% | +0.9% | +13.3% | |
| Q1 2024 | -9.1% | -1.9% | -9.0% | |
| Q4 2023 | +5.1% | -5.4% | -10.6% | |
| Q3 2023 | +6.0% | -0.1% | -9.3% | |
| Q2 2023 | +1.3% | +1.6% | +6.5% | |
| Q1 2023 | -9.5% | -13.3% | -12.9% | |
| Q4 2022 | -1.4% | -5.1% | -12.6% | |
| Q3 2022 | +0.7% | +6.5% | -3.0% | |
| Q2 2022 | -6.2% | +6.2% | +7.0% | |
| Q1 2022 | -11.6% | -10.1% | -14.3% | |
| Q4 2021 | -3.5% | -5.4% | -14.6% | |
| Q3 2021 | +8.9% | +2.9% | -11.2% | |
| Q2 2021 | -1.0% | +0.4% | +15.0% | |
| Q1 2021 | +3.0% | +10.5% | +0.6% | |
| Q4 2020 | +8.4% | +4.2% | -19.9% | |
| Q3 2020 | -1.5% | -0.3% | -18.7% | |
| Q2 2020 | -5.6% | -8.4% | -14.4% | |
| Q1 2020 | +0.2% | +13.0% | +10.3% | |
| Q4 2019 | +15.8% | +21.9% | -11.0% | |
| Q3 2019 | -71.3% | -69.6% | -61.2% | |
| Q2 2019 | -1.4% | -5.2% | -20.5% | |
| Q1 2019 | -6.8% | -0.7% | -3.5% | |
| Q4 2018 | -1.6% | -4.4% | +1.8% | |
| Q3 2018 | -16.1% | -19.0% | -16.5% | |
| Q2 2018 | +4.6% | +6.8% | +10.2% | |
| Q1 2018 | +0.5% | +0.6% | -18.8% | |
| Q4 2017 | -6.6% | -9.1% | -26.6% | |
| Q3 2017 | +1.3% | +2.7% | +37.1% | |
| Q2 2016 | +0.8% | -5.2% | +46.0% | |
| Q2 2017 | +0.8% | -5.2% | +46.0% | |
| Q1 2016 | -1.1% | +0.2% | -15.9% | |
| Q4 2016 | -1.1% | +7.4% | -12.4% | |
| Q1 2017 | +2.5% | +7.4% | -12.4% | |
| Q3 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro